Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs.

Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.

Feb 2 (Reuters) - Sanofi has breached the UK pharma code of practice with unsubstantiated claims that its Beyfortus was more ...

Pharmaceutical giant Pfizer (PFE) released its fourth quarter earnings results that topped Wall Street's expectations on its ...

Good day, everyone, and welcome to Pfizer's Fourth Quarter 2025 Earnings Conference Call. Today's call is being recorded. At ...

Pfizer (PFE) stock falls as the company posts mid-stage trial data for obesity therapy PF’3944. Read more here.

Pfizer reported strong mid-stage weight loss trial results for its monthly obesity drug and posted fourth-quarter earnings ...

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

To help answer common vaccine questions, we consulted Dr. Stanley Perlman, a professor at the University of Iowa’s Carver ...

Pfizer reported a quarterly loss Tuesday following a large write-down, denting shares as it confirmed 2026 financial targets ...

The U.S. stock market sank after a mixed day of trading. The S&P 500 fell 0.8% Tuesday. The Dow Jones Industrial Average ...

NEW YORK (AP) — NEW YORK (AP) — Pfizer Inc. (PFE) on Tuesday reported a loss of $1.65 billion in its fourth quarter. On a per-share basis, the New York-based company said it had a loss of 29 cents.